A randomized controlled trial for N-acetylcysteine in the treatment of severe alcoholic hepatitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030583

Enrollment

Unknown

Registered

2020-03-08

Start date

2016-06-01

Completion date

Unknown

Last updated

2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe alcoholic hepatitis

Interventions

NAC therapy group:Combined with NAC on the basis of comprehensive medicine

Control group:Comprehensive medical treatment

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Chinese citizens aged 18 to 60 (including 18 and 60), regardless of gender, meet the diagnostic criteria for severe alcoholic hepatitis; (2) There is no history of allergies to special drugs, and patients are willing to use NAC to treat patients.

Exclusion criteria

Exclusion criteria: (1) Combined with other liver diseases such as viral hepatitis, poisoning, genetic metabolic diseases, autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis), drug-induced liver damage, etc. Severe hepatitis, liver failure, liver failure; (2) Renal insufficiency; (3) Unable to cooperate with research or follow-up; (4) Those who may have undergone liver transplantation within the past week or have already undergone liver transplantation; (5) During pregnancy or lactation; (6) Conditions other doctors consider unsuitable for treatment.

Design outcomes

Primary

Measure	Time frame
survival rate;liver function;coagulation function;	—

Countries

China

Contacts

Public ContactBing Zhu

The fifth medical center of PLA General Hospital

zhubing302@163.com+86 13811633607

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026